Pancreatic adenocarcinoma is an important cause of death from cancer throughout the developed world. There are few established environmental risk factors, but a previous history of pancreatitis and exposure to tobacco and salted food appear to be the most important. A family history of pancreatic adenocarcinoma is not common in patients with this disease, but recent research has shown that pancreatic adenocarcinoma can be a feature of cancer susceptibility syndromes associated with gernmline mutations in p16, BRCA1, BRCA2, and APC. This highlights the need for a full family history in apparently sporadic cases. Somatic mutations in p16, BRCA2, and APC have also been reported in pancreatic cancer; however, K-RAS mutations appear to be the commonest oncogenic alteration. Recent advances in our understanding ofthe basis of hereditary cancer syndromes may be applicable to the diagnosis, treatment, and possibly prevention of pancreatic adenocarcinoma in the future. (J Med Genet 1996;33:889-898) 
Incidence, prevalence, and mortality There were approximately 185 000 new cases of pancreatic cancer world wide in 1980.1 This number represents 2.4% of all cancers, but the disease is most common in developed countries.'2 The highest age adjusted incidence rates are observed in Japan, eastern Europe, and North America (range for males 8.7-9.1, females 5.2-6.2 per 100 000) and the lowest age adjusted incidence rates are seen in north and west Africa and southern Asia (range for males 1.0-1.2, females 0.7-2.0 per 100 000).2 Some of these differences may be attributed to reporting bias, but they are probably too large to be the result of biases alone.
According to Canadian national statistics, it is estimated that 2950 Canadians will die of pancreatic cancer in 1996.' This will represent 4 .8% of all cancer deaths. Pancreatic cancer is the fifth commonest cause of cancer death in both men and women. Among Canadians, the lifetime probability of developing pancreatic cancer is just over 1 %, and has been increasing slightly over the last 20 years. Prevalence data confirm that the national five year survival is less than 10%.
Clinical features of pancreatic cancer DIAGNOSIS Detection of adenocarcinoma of the pancreas at an early, treatable stage is difficult because the disease lacks specific signs and symptoms. The cardinal features are pain, weight loss, and jaundice. Patients do not often survive longer than one year after diagnosis; early diagnosis is crucial to improving prognosis for pancreatic cancer patients. Diagnostic methods currently used include endoscopic and percutaneous ultrasonography, computerised tomography (CT), fine needle aspiration, CT guided fine needle aspiration, angiography, and endoscopic retrograde cholangiopancreatography.4 TREATMENT Treatment for pancreatic cancer is largely palliative since only 10-20% of pancreatic carcinomas are resectable and potentially curable, with a five year survival rate ofonly 4%. Surgical resection is the only curative treatment option available to date. It is usually combined with other forms of therapy such as preoperative, intraoperative, or postoperative radiation therapy. The tumour has a high resistance to chemotherapeutic agents. Strictly palliative therapies include bypass surgery and endoprostheses insertion for the relief of pain and obstructive jaundice, as well as analgesic drugs and nerve blockades.4
PROGNOSIS
The case/fatality ratio is 1 for pancreatic cancer; this is higher than for lung cancer (0.84) and brain tumours (0.68).' The average survival after diagnosis is less than six months; one year survival is less than 10%. In a review in 1977 it was noted that only 10% of patients were diagnosed at stage I of the disease. Of these, 40% lived for six months, 20% for one year, and only 2% survived for five years. In the vast majority of patients where the tumour had already metastasised by the time of diagnosis, the situation was even worse: 15% survived six months, 5% lived for one year, and none survived beyond two and a half years. 5 The situation has not changed significantly since then. The overall five year survival for pancreatic cancer in Quebec (1984 Quebec ( -1986 . In half the families, the disease was present in two consecutive generations; the pattern of cancer occurrence in these families appears to be consistent with an autosomal dominant mode of inheritance. One of these families is noteworthy (table 1, family 48). There is a total of four cases of pancreatic cancer over two generations. In the older generation, both sibs died of the disease; in the younger generation, four of the seven sibs have been diagnosed with cancer of the breast, ovary, lung, or pancreas. A fifth sib had double primary cancer of the breast (at the age of 39) and pancreas (at the age of 59). This is suggestive of a BRCA1 or BRCA2 related pattern of disease (discussed below).
Inherited syndromes in which pancreatic cancer is a feature (table 2) SYNDROMES WHERE CANCER IS THE DOMINANT FEATURE Familial atypical mole-multiple melanoma Pancreatic adenocarcinoma is probably the second commonest cancer in familial atypical mole-multiple melanoma (FAMMM) families (table 3) . The observed/expected (O/E) ratio for the frequency of pancreatic cancer among 200 members of nine FAMMM families was 13.4 (p<0.001).33 In several chromosome 9p linked FAMMM families, a mutation in the cell cycle inhibitor gene p 1 6INK4A has been found to cosegregate with both melanoma and pancreatic adenocarcinoma.3436 In some families, most persons with cancer have pancreatic or other gastrointestinal malignancies rather than melanoma. 37 This excess ofpancreatic cancer in FAMMM families may be attributed, in part, to ascertainment bias. Investigations of the tumour spectrum of the FAMMM syndrome showed no excess of pancreatic tumours in a total of 15 FAMMM kindreds and 370 people diagnosed with melanoma.38A0 However, there may be a biological explanation for the subset of FAMMM kindreds who have an excess of pancreatic cancer. In families where the p16INK4A mutation impairs the function of its corresponding protein in in vitro assays, the risk of pancreatic cancer was increased thirteenfold (standardised incidence ratio: 13.1, 95% CI 1.5-47.4), whereas no cases of pancreatic cancer were found in families with p16INK4A mutations that did not affect the function of the protein in the assay used by this group. 35 In the study of Whelan et al,37 a Gly93Trp missense mutation in p1 6INK4A was found in all 1) .4344 In these families, persons with pancreatic cancer have inherited the at risk haplotype and therefore it is likely that the pancreatic adenocarcinoma seen in these people is accounted for by BRCA1 (fig IA) or BRCA2 (fig 1B-D Somatic mutations of another tumour suppressor gene, APC, which is responsible for familial adenomatous polyposis (FAP), were detected in four of 10 pancreatic cancers. 89 There is an increased risk of pancreatic cancer in FAP62 (see above).
HOMOZYGOUS DELETIONS
Homozygous germline deletions are very uncommon, probably because of lethality during embryonic development. In tumour tissue, where there are less constraints, they are more common. Their presence has aided the discovery of tumour suppressor genes. Thus the isolation of tumour suppressor genes RB 1, DCC, and p16I 4A was made easier by the presence of homozygous deletions in tumour tissue.849091 In pancreatic neoplasms, this genetic alteration has been reported at three loci: 13q, 9p, and 18q.
Using the powerful representational difference analysis (RDA) technique,92 Schutte et al93 discovered two clones that were present only in the germline of a patient with pancreatic cancer. Intriguingly, both these clones, named Deleted in Pancreatic Cancer locus 1 (DPC1) and DPC2, mapped to a region of chromosome 13q that lay within the smallest linked region of BRCA2. The patient was an 84 year old woman with localised pancreatic adenocarcinoma. There was a strong family history of adenocarcinomata, mainly at an advanced age. Although there was no suggestion of a germline mutation in BRCA2 in this family, the position of this homozygous deletion was a significant help in the search for BRCA2, which was cloned less than six months after the paper was published. It is now known that BRCA2 lies completely within this deletion. LOH at 18q spanned the entire DCC area, but it is likely that the recently described DPC4 gene is the target for this region of LOH. The FAL was 0.36; this higher figure is probably because of the xenograft enrichment, as pancreatic cancer is often accompanied by a marked host desmoplastic reaction. The LOH on chromosomes 9p, 17p, and 18q can probably be accounted for by p16INK4A, TP53, and DPC4, respectively, but it is likely that other genes of relevance to pancreatic adenocarcinoma remain to be uncovered. 
